Clinical Study to Evaluate ctDNA Test for Guiding Lung Cancer Treatment
Haystack Oncology and Rutgers Cancer Institute collaborate on phase II trial examining minimal residual disease testing in stage II/III NSCLC patients.
Read More
Search Results for: lung cancer
CRISPR-Based TB Test Detects Infection From Tongue Swabs
The test showed 74% detection rate in tongue swabs compared to 56% with traditional testing methods that rely on difficult-to-collect sputum samples.
Read More
Circulating Tumor DNA Shows Promise for Guiding Immunotherapy in Lung Cancer
Study of 177 patients with limited-stage small cell lung cancer demonstrates ctDNA’s potential to personalize consolidation immunotherapy decisions.
Read More
Roche Gains CE IVDR Approval for Expanded HER2 Companion Diagnostic
VENTANA HER2 (4B5) test is now CE-IVDR approved to identify HER2-ultralow breast cancer and HER2-positive biliary tract cancer patients.
Read More
Foresight Diagnostics Reports Clinical Performance Data for ctDNA Assay in Early-Stage Lung Cancer
Study shows Foresight CLARITY demonstrated 68% pre-operative and 38% post-operative MRD detection rates in stage I lung cancer patients.
Read More